Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

180 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Association of the practice of contact sports with the development of amyotrophic lateral sclerosis.
Henriques AR, Gromicho M, Grosskreutz J, Kuzma-Kozakiewicz M, Petri S, Uysal H, Pinto S, Antunes M, De Carvalho M, Ribeiro RM. Henriques AR, et al. Among authors: grosskreutz j. Amyotroph Lateral Scler Frontotemporal Degener. 2023 Aug;24(5-6):449-456. doi: 10.1080/21678421.2023.2189911. Epub 2023 Mar 29. Amyotroph Lateral Scler Frontotemporal Degener. 2023. PMID: 36992635
A randomized, double blind, placebo-controlled trial of pioglitazone in combination with riluzole in amyotrophic lateral sclerosis.
Dupuis L, Dengler R, Heneka MT, Meyer T, Zierz S, Kassubek J, Fischer W, Steiner F, Lindauer E, Otto M, Dreyhaupt J, Grehl T, Hermann A, Winkler AS, Bogdahn U, Benecke R, Schrank B, Wessig C, Grosskreutz J, Ludolph AC; GERP ALS Study Group. Dupuis L, et al. Among authors: grosskreutz j. PLoS One. 2012;7(6):e37885. doi: 10.1371/journal.pone.0037885. Epub 2012 Jun 8. PLoS One. 2012. PMID: 22715372 Free PMC article. Clinical Trial.
The involvement of the cerebellum in amyotrophic lateral sclerosis.
Prell T, Grosskreutz J. Prell T, et al. Among authors: grosskreutz j. Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):507-15. doi: 10.3109/21678421.2013.812661. Epub 2013 Jul 29. Amyotroph Lateral Scler Frontotemporal Degener. 2013. PMID: 23889583 Review.
Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial.
Cudkowicz ME, van den Berg LH, Shefner JM, Mitsumoto H, Mora JS, Ludolph A, Hardiman O, Bozik ME, Ingersoll EW, Archibald D, Meyers AL, Dong Y, Farwell WR, Kerr DA; EMPOWER investigators. Cudkowicz ME, et al. Lancet Neurol. 2013 Nov;12(11):1059-67. doi: 10.1016/S1474-4422(13)70221-7. Epub 2013 Sep 23. Lancet Neurol. 2013. PMID: 24067398 Clinical Trial.
Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS.
Oeckl P, Jardel C, Salachas F, Lamari F, Andersen PM, Bowser R, de Carvalho M, Costa J, van Damme P, Gray E, Grosskreutz J, Hernández-Barral M, Herukka SK, Huss A, Jeromin A, Kirby J, Kuzma-Kozakiewicz M, Amador Mdel M, Mora JS, Morelli C, Muckova P, Petri S, Poesen K, Rhode H, Rikardsson AK, Robberecht W, Rodríguez Mahillo AI, Shaw P, Silani V, Steinacker P, Turner MR, Tüzün E, Yetimler B, Ludolph AC, Otto M. Oeckl P, et al. Among authors: grosskreutz j. Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):404-13. doi: 10.3109/21678421.2016.1167913. Epub 2016 Apr 11. Amyotroph Lateral Scler Frontotemporal Degener. 2016. PMID: 27415180
Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis.
van Rheenen W, Shatunov A, Dekker AM, McLaughlin RL, Diekstra FP, Pulit SL, van der Spek RA, Võsa U, de Jong S, Robinson MR, Yang J, Fogh I, van Doormaal PT, Tazelaar GH, Koppers M, Blokhuis AM, Sproviero W, Jones AR, Kenna KP, van Eijk KR, Harschnitz O, Schellevis RD, Brands WJ, Medic J, Menelaou A, Vajda A, Ticozzi N, Lin K, Rogelj B, Vrabec K, Ravnik-Glavač M, Koritnik B, Zidar J, Leonardis L, Grošelj LD, Millecamps S, Salachas F, Meininger V, de Carvalho M, Pinto S, Mora JS, Rojas-García R, Polak M, Chandran S, Colville S, Swingler R, Morrison KE, Shaw PJ, Hardy J, Orrell RW, Pittman A, Sidle K, Fratta P, Malaspina A, Topp S, Petri S, Abdulla S, Drepper C, Sendtner M, Meyer T, Ophoff RA, Staats KA, Wiedau-Pazos M, Lomen-Hoerth C, Van Deerlin VM, Trojanowski JQ, Elman L, McCluskey L, Basak AN, Tunca C, Hamzeiy H, Parman Y, Meitinger T, Lichtner P, Radivojkov-Blagojevic M, Andres CR, Maurel C, Bensimon G, Landwehrmeyer B, Brice A, Payan CA, Saker-Delye S, Dürr A, Wood NW, Tittmann L, Lieb W, Franke A, Rietschel M, Cichon S, Nöthen MM, Amouyel P, Tzourio C, Dartigues JF, Uitterlinden AG, Rivadeneira F, Estrada K, Hofman A, Curtis C, Blauw HM, van der Kooi AJ, de Visser M, Goris A… See abstract for full author list ➔ van Rheenen W, et al. Among authors: grosskreutz j. Nat Genet. 2016 Sep;48(9):1043-8. doi: 10.1038/ng.3622. Epub 2016 Jul 25. Nat Genet. 2016. PMID: 27455348 Free PMC article.
Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net.
Steinacker P, Huss A, Mayer B, Grehl T, Grosskreutz J, Borck G, Kuhle J, Lulé D, Meyer T, Oeckl P, Petri S, Weishaupt J, Ludolph AC, Otto M. Steinacker P, et al. Among authors: grosskreutz j. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):112-119. doi: 10.1080/21678421.2016.1241279. Epub 2016 Nov 5. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 27819158
Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
Meininger V, Genge A, van den Berg LH, Robberecht W, Ludolph A, Chio A, Kim SH, Leigh PN, Kiernan MC, Shefner JM, Desnuelle C, Morrison KE, Petri S, Boswell D, Temple J, Mohindra R, Davies M, Bullman J, Rees P, Lavrov A; NOG112264 Study Group. Meininger V, et al. Lancet Neurol. 2017 Mar;16(3):208-216. doi: 10.1016/S1474-4422(16)30399-4. Epub 2017 Jan 28. Lancet Neurol. 2017. PMID: 28139349 Free article. Clinical Trial.
180 results